Call for Papers
ASH Summit on Immunotherapies for Hematologic Diseases
-
Call For papers
-
Eligibility
-
Responsibilities
-
Technical Requirements
-
Before you Begin
-
FAQs
In response to the ongoing COVID-19 pandemic and the emerging evidence about the Omicron variant, ASH has decided to postpone the March 2022 Summit on Immunotherapies for Hematologic Diseases to early 2023. The health and safety of our meeting attendees remain ASH’s top priority. Please check back for updates.
Abstracts must be submitted online through the official online abstract submission system. E-mails and word processing files not submitted through the online submission system will not be accepted.
Make sure to read the complete abstract submission policies on the ASH website.
Eligibility
To submit an abstract research and/or studies must fit into one of the ASH Summit on Immunotherapies for Hematologic Diseases Abstract Review Categories.
Any of the following criteria will make an abstract ineligible for presentation at the ASH Summit on Immunotherapies for Hematologic Diseases:
- Data are publicly available via major search engines (such as PubMed, Google Scholar, etc.).
- Data are accepted for publication before the abstract submission deadline.
- Data have been or are to be presented at a meeting of 1,000 or more participants before the ASH Summit on Immunotherapies for Hematologic Diseases.*
- Contact by corresponding authors, presenters, and co-authors made to known or potential reviewers to promote or otherwise attempt to influence the outcome of the review process.
* Abstracts accepted for presentation or publication for the ASH 2021 Annual Meeting are exempted from the above restrictions.
Note: Abstracts submitted to the ASH Summit on Immunotherapies for Hematologic Diseases are eligible to be re-submitted to the 2022 ASH Annual Meeting.
Responsibilities of the Presenting Author
The presenting author must be one of the co-authors listed on the submitted abstract and serves as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the “Contact Information” section of the online abstract submission system.
IMPORTANT: The presenting author will not be considered for an oral presentation if he or she owns or is employed by a commercial interest. Please note, a commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
The presenting author is responsible for:
- Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
- Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ASH.
- Obtaining all co-authors’ conflict-of-interest disclosure Conflict-of-Interest Disclosure Policy and copyright transfer information.
- Forwarding all correspondence to all co-authors, including ASH policies and guidelines and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support for Continuing Medical Education (CME).
Technical Requirements
The electronic submission system is compatible with PC Windows and Apple computers and with most browsers, including Mozilla Firefox, Internet Explorer, Safari, and Netscape.
Have the following information available:
Abstract Information
- Abstract Review Category
- Authors must indicate during online submission the appropriate review category (one only). Please refer to the list of abstract review categories, which provides detailed descriptions of each category, to assist you in selecting the correct abstract classification. Read through all of the categories and select the category most closely associated with your abstract.
- Note that the abstract will be reviewed in the category you selected; there is no re-classification once submission has closed.
- Abstracts submitted to the wrong category are scored in that category and usually fare poorly.
- Abstract Title
- The abstract title should be brief and clearly indicate the nature of the abstract.
- The abstract title must be in title case. Capitalize all nouns, pronouns, adjectives, verbs, adverbs, and subordinate conjunctions (i.e., as, because, although). Except for the first word of the title, lowercase all articles, coordinate conjunctions (i.e., and, or, nor), and prepositions, regardless of length. Also, lowercase “to” when used as an infinitive. Additionally, keep letters lowercase if the lowercase letters have a specific meaning, such as pH or NaCl.
- Do not put a period at the end of the title.
For example: Somatic Mutations in Schinzel-Giedion Syndrome Gene SETBP1 Determine Progression in Myeloid Malignancies
- Once you have submitted the title page information, a draft of your abstract will be saved, and you will be able to return to edit and update it at any time until the abstract submission deadline. You will receive an e-mail providing a link to your submission.
- Keywords
- Abstract Text
- Abstracts will be typeset from the text submitted by the author without copyediting changes. It is the responsibility of the author to proofread the abstract carefully.
- The entire text of the abstract must not exceed 3,800 characters. Spaces are not included in this number. Title, authors’ names, affiliations, figures, and tables are not included in the character count.
- The abstract may be structured (i.e., abstracts divided into sections using terms such as Introduction, Methods, Results, Conclusions, etc.) or unstructured.
- Do not use bold type or underline formatting. Italic type is acceptable.
- Text may be in multiple paragraphs.
- Special Greek and mathematical symbols are available in a character map within the submission system.
- Use numerals to indicate numbers, except when beginning sentences.
- Use of Product Names: Non-proprietary (generic/scientific) names should be used and should be lowercase. If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalized. ASH reserves the right to replace proprietary names with generic names to adhere to this policy.
- Abbreviations: Use standard abbreviations. Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract.
- Any references should be noted as citations within the text and not as footnotes at the end.
- Figures and Tables
- ASH will only be accepting a single image upload for abstract submission, but that image may contain multiple tables and figures. Any tables that you wish to include must be uploaded as part of the image. Please do not paste a table directly into the text of the abstract, but rather include it in the image upload.
Person Information
Your name, degree, institution, address, phone number, and email address must be provided. If you are the corresponding author, you will receive all future correspondence from ASH. The corresponding author should be the first author (presenter) of the abstract, unless otherwise noted during submission.
For each author listed on the abstract, indicate:
- Name: Names of co-authors and institutions must be provided. The program will automatically place an asterisk (*) after the name of each non-member author. Changes will not be made to the spelling of authors’ names after the submission deadline; please proofread your co-authors’ names carefully.
When adding authors to the abstract, you will be able to search the ASH membership database. Be sure to always use a matching result, even if some of the contact information displayed is out of date. You will be given the opportunity to update it after selecting it. Do not enter a person from scratch if they already exist in the database.
- Affiliation: You must enter the identical information for the Affiliation, Department, City, and Country fields, if you desire co-authors’ affiliations to be grouped properly. If the information in one of these fields deviates from other co-author(s) that should be grouped together under one affiliation, there will be a new affiliation listed and it would therefore not group with others that you had intended. For example: If you list one person's department as "Department of Hematology" and another person's department as "Hematology", these will not group properly. They must be the same, like "Department of Hematology".
- Email Address: The email address should match the email in ASH's membership database (if applicable). For authors who are ASH members the e-mail address on file with ASH should be used. If that e-mail address is no longer their preferred address, the current preferred e-mail should be updated with the ASH membership department FIRST.
- Alternate E-mail Address (optional)
- Mailing Address
- Conflict-of-Interest Disclosure Information. See “Responsibilities of the Presenting Author” for more guidance on disclosures.
Payment Information
There is a $60 non-refundable handling fee for submitting an abstract. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted.
- It is not a requirement that payment be made by an author listed on the abstract. However, you should have the appropriate payment information - name on the credit card, the card number and expiration date - in hand before you begin submitting.
- Abstracts cannot be submitted and will not be reviewed without proper payment and completion of all steps of the online abstract submission program.
FAQS
Please consider the following before submitting your abstract to the ASH Summit on Immunotherapies for Hematologic Diseases:
- Q: What is the submission deadline for the abstracts?
A: The deadline for all abstracts is Tuesday January 25, 2022 at 11:59 p.m. PDT. Submissions that are incomplete at this time will be rejected without review.
- Q: Can I still submit an abstract if I presented it at another scientific meeting or submitted it to a journal?
A: Any of the following criteria will make an abstract ineligible for presentation at the ASH Summit on Immunotherapies for Hematologic Diseases:
- Data are publicly available via major search engines (such as PubMed, Google Scholar, etc.).
- Data are accepted for publication before the abstract submission closing date.
- Data have been or are to be presented at a meeting of 1,000 or more participants before the ASH Summit on Immunotherapies for Hematologic Diseases.*
- Contact by corresponding authors, presenters, and co-authors made to known or potential reviewers to promote or otherwise attempt to influence the outcome of the review process.
* Abstracts accepted for presentation or publication for the ASH 2021 Annual Meeting are exempted from the above restrictions.
Note: Abstracts submitted to the ASH Summit on Immunotherapies for Hematologic Diseases are eligible to be re-submitted to the 2022 ASH Annual Meeting.
- Q: How long can the abstracts be?
A: The abstracts are limited to a maximum of 3,800 characters. Note that this character count does not include spaces but does include the space allocated to tables. Figures are not included in the character count.
- Q: May I include tables in my abstract?
A: Yes, but we now ask that any tables that you wish to include must be uploaded as an image. You will not be allowed to paste a table directly into the text of the abstract, but rather you must include it as an image in the appropriate place and use the Upload method. To convert a table to an image, we recommend taking a screenshot of the table. If using a PC, use the Snipping Tool or the Print Screen button. If using a Mac, press Command-Shift-4.
- Q: If I have images in my abstract, what resolution should my images be?
A: We require a minimum of 300 dpi for all uploaded images. This will insure proper resolution for display.
- Q: How many abstracts can a single author submit?
A: There is no set limit as to the number of abstracts a single author can submit.
- Q: How many authors can contribute to a single abstract?
A: There is no set limit to the number of authors who can contribute to a single abstract.
- Q: Do all authors on an abstract have to submit their Conflict-of-Interest disclosures to ASH? How should they do that?
A: The submitting author must manually enter disclosure information for all authors into the online abstract submission form. Authors must disclose all relationships they may have, regardless of their relevance to an abstract. If an author's COI disclosure form populates with information already supplied, we strongly urge you to use this existing information for that person. If you are aware of a relationship that should be added to that disclosure, you may do so, and the update will be applied to all that individual's disclosures for the entire meeting. Please do NOT delete any existing disclosure information if you are not the person in question. You may wish to use this sample form to collect disclosure information from your coauthors. (Please note that this form should NOT be sent to ASH; you are responsible for entering the information on the form into the online abstract submission system for every author.)
- Q: What if I am not able to submit my abstract at this time?
A: You may consider submitting your abstract to the 2022 ASH Annual Meeting. Check the Call for Abstracts webpage to learn more about the ASH Annual Meeting.
- Q: When will I know if my abstract has been accepted?
A: You will receive an e-mail in mid-February notifying you if your abstract has been accepted..
- Q: What if I need to withdraw my abstract?
A: If an abstract author decides to withdraw an abstract for any reason:
- When it is before the abstract submission deadline, the submitting author can withdraw the abstract in the online submission system.
- When it is after the abstract submission deadline has passed, authors must request to withdraw abstracts via submitting an email to ashsummit@hematology.org. Once an abstract is accepted, a written request to withdraw must be submitted no later than March 1, 2022, to ashsummit@hematology.org if the author decides to withdraw the abstract for any reason. Abstract withdrawal requests received after the deadline will be considered on a case-by-case basis.
- ASH reserves the right to withdraw abstracts that are in violation of the Society’s policies and guidelines, such as those that have been previously published or presented (except at the most recent ASH annual meeting), have been deemed scientifically unsound, or have been found to include inaccurate data, etc.
- Q: When will my accepted abstract be published?
A: All abstracts accepted for presentation will be made available only to registered attendees as part of the meeting program. Abstracts will not be published or made available to the public in any form.
- Call For papers
- Eligibility
- Responsibilities
- Technical Requirements
- Before you Begin
- FAQs
In response to the ongoing COVID-19 pandemic and the emerging evidence about the Omicron variant, ASH has decided to postpone the March 2022 Summit on Immunotherapies for Hematologic Diseases to early 2023. The health and safety of our meeting attendees remain ASH’s top priority. Please check back for updates.
Abstracts must be submitted online through the official online abstract submission system. E-mails and word processing files not submitted through the online submission system will not be accepted.
Make sure to read the complete abstract submission policies on the ASH website.
Eligibility
To submit an abstract research and/or studies must fit into one of the ASH Summit on Immunotherapies for Hematologic Diseases Abstract Review Categories.
Any of the following criteria will make an abstract ineligible for presentation at the ASH Summit on Immunotherapies for Hematologic Diseases:
- Data are publicly available via major search engines (such as PubMed, Google Scholar, etc.).
- Data are accepted for publication before the abstract submission deadline.
- Data have been or are to be presented at a meeting of 1,000 or more participants before the ASH Summit on Immunotherapies for Hematologic Diseases.*
- Contact by corresponding authors, presenters, and co-authors made to known or potential reviewers to promote or otherwise attempt to influence the outcome of the review process.
* Abstracts accepted for presentation or publication for the ASH 2021 Annual Meeting are exempted from the above restrictions.
Note: Abstracts submitted to the ASH Summit on Immunotherapies for Hematologic Diseases are eligible to be re-submitted to the 2022 ASH Annual Meeting.
Responsibilities of the Presenting Author
The presenting author must be one of the co-authors listed on the submitted abstract and serves as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the “Contact Information” section of the online abstract submission system.
IMPORTANT: The presenting author will not be considered for an oral presentation if he or she owns or is employed by a commercial interest. Please note, a commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
The presenting author is responsible for:
- Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
- Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ASH.
- Obtaining all co-authors’ conflict-of-interest disclosure Conflict-of-Interest Disclosure Policy and copyright transfer information.
- Forwarding all correspondence to all co-authors, including ASH policies and guidelines and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support for Continuing Medical Education (CME).
Technical Requirements
The electronic submission system is compatible with PC Windows and Apple computers and with most browsers, including Mozilla Firefox, Internet Explorer, Safari, and Netscape.
Have the following information available:
Abstract Information
- Abstract Review Category
- Authors must indicate during online submission the appropriate review category (one only). Please refer to the list of abstract review categories, which provides detailed descriptions of each category, to assist you in selecting the correct abstract classification. Read through all of the categories and select the category most closely associated with your abstract.
- Note that the abstract will be reviewed in the category you selected; there is no re-classification once submission has closed.
- Abstracts submitted to the wrong category are scored in that category and usually fare poorly.
- Abstract Title
- The abstract title should be brief and clearly indicate the nature of the abstract.
- The abstract title must be in title case. Capitalize all nouns, pronouns, adjectives, verbs, adverbs, and subordinate conjunctions (i.e., as, because, although). Except for the first word of the title, lowercase all articles, coordinate conjunctions (i.e., and, or, nor), and prepositions, regardless of length. Also, lowercase “to” when used as an infinitive. Additionally, keep letters lowercase if the lowercase letters have a specific meaning, such as pH or NaCl.
- Do not put a period at the end of the title.
For example: Somatic Mutations in Schinzel-Giedion Syndrome Gene SETBP1 Determine Progression in Myeloid Malignancies - Once you have submitted the title page information, a draft of your abstract will be saved, and you will be able to return to edit and update it at any time until the abstract submission deadline. You will receive an e-mail providing a link to your submission.
- Keywords
- Abstract Text
- Abstracts will be typeset from the text submitted by the author without copyediting changes. It is the responsibility of the author to proofread the abstract carefully.
- The entire text of the abstract must not exceed 3,800 characters. Spaces are not included in this number. Title, authors’ names, affiliations, figures, and tables are not included in the character count.
- The abstract may be structured (i.e., abstracts divided into sections using terms such as Introduction, Methods, Results, Conclusions, etc.) or unstructured.
- Do not use bold type or underline formatting. Italic type is acceptable.
- Text may be in multiple paragraphs.
- Special Greek and mathematical symbols are available in a character map within the submission system.
- Use numerals to indicate numbers, except when beginning sentences.
- Use of Product Names: Non-proprietary (generic/scientific) names should be used and should be lowercase. If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalized. ASH reserves the right to replace proprietary names with generic names to adhere to this policy.
- Abbreviations: Use standard abbreviations. Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract.
- Any references should be noted as citations within the text and not as footnotes at the end.
- Figures and Tables
- ASH will only be accepting a single image upload for abstract submission, but that image may contain multiple tables and figures. Any tables that you wish to include must be uploaded as part of the image. Please do not paste a table directly into the text of the abstract, but rather include it in the image upload.
Person Information
Your name, degree, institution, address, phone number, and email address must be provided. If you are the corresponding author, you will receive all future correspondence from ASH. The corresponding author should be the first author (presenter) of the abstract, unless otherwise noted during submission.
For each author listed on the abstract, indicate:
- Name: Names of co-authors and institutions must be provided. The program will automatically place an asterisk (*) after the name of each non-member author. Changes will not be made to the spelling of authors’ names after the submission deadline; please proofread your co-authors’ names carefully.
When adding authors to the abstract, you will be able to search the ASH membership database. Be sure to always use a matching result, even if some of the contact information displayed is out of date. You will be given the opportunity to update it after selecting it. Do not enter a person from scratch if they already exist in the database.
- Affiliation: You must enter the identical information for the Affiliation, Department, City, and Country fields, if you desire co-authors’ affiliations to be grouped properly. If the information in one of these fields deviates from other co-author(s) that should be grouped together under one affiliation, there will be a new affiliation listed and it would therefore not group with others that you had intended. For example: If you list one person's department as "Department of Hematology" and another person's department as "Hematology", these will not group properly. They must be the same, like "Department of Hematology".
- Email Address: The email address should match the email in ASH's membership database (if applicable). For authors who are ASH members the e-mail address on file with ASH should be used. If that e-mail address is no longer their preferred address, the current preferred e-mail should be updated with the ASH membership department FIRST.
- Alternate E-mail Address (optional)
- Mailing Address
- Conflict-of-Interest Disclosure Information. See “Responsibilities of the Presenting Author” for more guidance on disclosures.
Payment Information
There is a $60 non-refundable handling fee for submitting an abstract. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted.
- It is not a requirement that payment be made by an author listed on the abstract. However, you should have the appropriate payment information - name on the credit card, the card number and expiration date - in hand before you begin submitting.
- Abstracts cannot be submitted and will not be reviewed without proper payment and completion of all steps of the online abstract submission program.
FAQS
Please consider the following before submitting your abstract to the ASH Summit on Immunotherapies for Hematologic Diseases:
- Q: What is the submission deadline for the abstracts?
A: The deadline for all abstracts is Tuesday January 25, 2022 at 11:59 p.m. PDT. Submissions that are incomplete at this time will be rejected without review. - Q: Can I still submit an abstract if I presented it at another scientific meeting or submitted it to a journal?
A: Any of the following criteria will make an abstract ineligible for presentation at the ASH Summit on Immunotherapies for Hematologic Diseases:- Data are publicly available via major search engines (such as PubMed, Google Scholar, etc.).
- Data are accepted for publication before the abstract submission closing date.
- Data have been or are to be presented at a meeting of 1,000 or more participants before the ASH Summit on Immunotherapies for Hematologic Diseases.*
- Contact by corresponding authors, presenters, and co-authors made to known or potential reviewers to promote or otherwise attempt to influence the outcome of the review process.
* Abstracts accepted for presentation or publication for the ASH 2021 Annual Meeting are exempted from the above restrictions.
Note: Abstracts submitted to the ASH Summit on Immunotherapies for Hematologic Diseases are eligible to be re-submitted to the 2022 ASH Annual Meeting.
- Q: How long can the abstracts be?
A: The abstracts are limited to a maximum of 3,800 characters. Note that this character count does not include spaces but does include the space allocated to tables. Figures are not included in the character count. - Q: May I include tables in my abstract?
A: Yes, but we now ask that any tables that you wish to include must be uploaded as an image. You will not be allowed to paste a table directly into the text of the abstract, but rather you must include it as an image in the appropriate place and use the Upload method. To convert a table to an image, we recommend taking a screenshot of the table. If using a PC, use the Snipping Tool or the Print Screen button. If using a Mac, press Command-Shift-4. - Q: If I have images in my abstract, what resolution should my images be?
A: We require a minimum of 300 dpi for all uploaded images. This will insure proper resolution for display. - Q: How many abstracts can a single author submit?
A: There is no set limit as to the number of abstracts a single author can submit. - Q: How many authors can contribute to a single abstract?
A: There is no set limit to the number of authors who can contribute to a single abstract. - Q: Do all authors on an abstract have to submit their Conflict-of-Interest disclosures to ASH? How should they do that?
A: The submitting author must manually enter disclosure information for all authors into the online abstract submission form. Authors must disclose all relationships they may have, regardless of their relevance to an abstract. If an author's COI disclosure form populates with information already supplied, we strongly urge you to use this existing information for that person. If you are aware of a relationship that should be added to that disclosure, you may do so, and the update will be applied to all that individual's disclosures for the entire meeting. Please do NOT delete any existing disclosure information if you are not the person in question. You may wish to use this sample form to collect disclosure information from your coauthors. (Please note that this form should NOT be sent to ASH; you are responsible for entering the information on the form into the online abstract submission system for every author.) - Q: What if I am not able to submit my abstract at this time?
A: You may consider submitting your abstract to the 2022 ASH Annual Meeting. Check the Call for Abstracts webpage to learn more about the ASH Annual Meeting. - Q: When will I know if my abstract has been accepted?
A: You will receive an e-mail in mid-February notifying you if your abstract has been accepted.. - Q: What if I need to withdraw my abstract?
A: If an abstract author decides to withdraw an abstract for any reason:- When it is before the abstract submission deadline, the submitting author can withdraw the abstract in the online submission system.
- When it is after the abstract submission deadline has passed, authors must request to withdraw abstracts via submitting an email to ashsummit@hematology.org. Once an abstract is accepted, a written request to withdraw must be submitted no later than March 1, 2022, to ashsummit@hematology.org if the author decides to withdraw the abstract for any reason. Abstract withdrawal requests received after the deadline will be considered on a case-by-case basis.
- ASH reserves the right to withdraw abstracts that are in violation of the Society’s policies and guidelines, such as those that have been previously published or presented (except at the most recent ASH annual meeting), have been deemed scientifically unsound, or have been found to include inaccurate data, etc.
- Q: When will my accepted abstract be published?
A: All abstracts accepted for presentation will be made available only to registered attendees as part of the meeting program. Abstracts will not be published or made available to the public in any form.